Skip to main content
. 2020 Dec 29;6(3):806–809. doi: 10.1016/j.ekir.2020.12.024

Table 2.

Demographics, clinical characteristics, and outcomes of patients with COVID-19 on a background of established ANCA-associated vasculitis

Case report Age Gender Ethnicity Peak creatinine (mg/dl) Duration of ANCA diagnosis (mo) ANCA type Lung radiology ANCA maintenance Last IS to COVID diagnosis (d) RRT Respiratory failure COVID-19 treatment COVID-19 outcome Comments
Guilpain2 52 F NR NR 396 PR3 Bilateral interstitial pneumonia RTX 1 No MV Lopinavir/ritonavir; HCQ Recovered from respiratory failure; discharged on day 29 of admission Received RTX a day prior to COVID presentation
SharmeenS7 27 F Hispanic NR 1 PR3 Bilateral multifocal opacities RTX, prednisone (20 mg) 60 No NRB, 15 L HCQ, tocilizumab Recovered On 20 mg prednisone at the time of COVID diagnosis
SchrammS8 25 M NR NR 2 PR3 Bilateral GGOs RTX, CYC (induction), prednisone (60 mg) 9 No Low-flow, 2 L HCQ, lopinavir/ritonavir Recovered Nosocomial infection
Ongoing 60 mg prednisone, 9 d after last of 5 cyclophosphamide infusions and 19 d after the last of 4 rituximab infusions
Daniel3 55 M NR NR 324 PR3 Bilateral GGOs (60% involvement) RTX, prednisone (4 mg) 120 No None HCQ, azithromycin, lopinavir/ritonavir Recovered, discharged home after 23 d On 4 mg prednisone at the time of diagnosis
LeipeS9 63 M NR 3.4 72 PR3 Bilateral GGOs RTX, prednisone (5 mg) 14 No Face mask, 6 L None Readmitted with worsening respiratory symptoms on day 14; eventual recovery On 5 mg prednisone at the time of diagnosis
ShenavandehS10 35 M NR NR 72 PR3 Multiple new left-sided peripheral GGOs in addition to the pre-existing right-side cavitary lesion RTX, AZA, prednisone (7.5 mg) NR No None HCQ, azithromycin Discharged after 4 d; recovered On 7.5 mg prednisone at the time of diagnosis
FalletS11 77 F NR NR 24 PR3 Scattered bilateral GGOs RTX, MTX, prednisone 5 mg 30 No None None Discharged after 6 d; recovered
Suárez-DiazS12 64 F NR NR 72 MPO NR Prednisone 5 mg 90 No None None Recovered at home Treated for vasculitis relapse with RTX 90 d before COVID diagnosis
Current study 74 F African American 1.5 108 MPO Scattered bilateral GGOs Prednisone 5 mg No MV Remdesivir Recovered Renal biopsy showed mild necrotizing GN; received MP 40 mg × 10; RTX 2 mo after COVID diagnosis
Current study 48 F Hispanic 0.7 72 PR3 Diffuse peribronchovascular and peripheral GGOs RTX 500 mg, prednisone 8 mg 60 No HFNC Remdesivir, Dexamethasone Recovered
Current study 81 F African American 1.5 12 PR3 Scattered bilateral GGOs AZA, prednisone 5 mg No HFNC None Recovered
Current study 45 M Asian 1.3 60 PR3 Scattered bilateral GGOs RTX, prednisone 5 mg 120 No Low flow, 2 L Remdesivir Recovered
Current study 63 M Caucasian 1.2 0.5 PR3 Scattered bilateral GGOs See comments 7 No Low-flow, 6 L Dexamethasone, remdesivir, convalescent plasma In-hospital Received RTX 1 g and MP 500 mg × 3 for induction. Diagnosed with COVID a week after RTX and discharged from hospital.
Current study 36 M Caucasian 1 54 PR3 RTX 80 No None None Recovered at home

ANCA, antineutrophil cytoplasmic antibody; AZA, azathioprine; COVID, coronavirus disease 2019; CYC, cyclophosphamide; F, female; GGOs, ground-glass opacities; GN, glomerulonephritis; HCQ, hydroxychloroquine; HFNC, high-flow nasal cannula; iHD, intermittent hemodialysis; IS, immunosuppression; M, male; MP, methylprednisone; MPO, myeloperoxidase antibody; MTX, methotrexate; MV, mechanical ventilation; NR, not reported; NRB, nonrebreather mask; PR3, proteinase 3; RRT, renal replacement therapy; RTX, rituximab; UA, urinalysis.